v3.26.1
Borrowings - 2024-1 CLO Debt (Details) - USD ($)
 6 Months Ended
Jun. 30, 2026
Dec. 31, 2025
Nov. 21, 2024
Debt Instrument [Line Items]      
Aggregate Principal Committed $ 10,411,130,000 $ 10,507,500,000  
Principal outstanding 7,613,729,000 8,100,621,000  
Investments at fair value 13,364,295,000 14,207,294,000  
Restricted cash 83,737,000 89,406,000  
Cash and cash equivalents 267,155,000 289,605,000  
Total assets 13,788,668,000 14,656,463,000  
Debt 7,536,067,000 8,080,129,000  
Unamortized Debt Issuance Costs (including premiums and discounts) 51,435,000 39,900,000  
Interest payable 62,772,000 61,952,000  
Total liabilities 7,849,935,000 8,411,288,000  
2024-1 Issuer      
Debt Instrument [Line Items]      
Investments at fair value 712,168,000 727,232,000  
Restricted cash 83,737,000 89,406,000  
Cash and cash equivalents 83,737,000 89,406,000  
Total assets 800,991,000 825,929,000  
Debt 455,389,000 455,288,000  
Unamortized Debt Issuance Costs (including premiums and discounts) 2,111,000 2,212,000  
Interest payable 4,769,000 5,029,000  
Total liabilities 460,158,000 460,317,000  
Non-controlled/non-affiliated investments      
Debt Instrument [Line Items]      
Investments at fair value 13,221,914,000 [1],[2] 14,167,499,000 [3],[4]  
Interest receivable from non-controlled/non-affiliated investments 107,926,000 105,695,000  
Non-controlled/non-affiliated investments | 2024-1 Issuer      
Debt Instrument [Line Items]      
Investments at fair value 712,168,000 727,232,000  
Interest receivable from non-controlled/non-affiliated investments 5,086,000 9,291,000  
2024-1 CLO Debt      
Debt Instrument [Line Items]      
Aggregate Principal Committed 457,500,000 457,500,000  
Principal outstanding 746,770,000    
Debt 455,389,000 455,288,000  
Unamortized Debt Issuance Costs (including premiums and discounts) 2,111,000 $ 2,212,000  
Secured debt | 2024-1 CLO Debt      
Debt Instrument [Line Items]      
Aggregate Principal Committed     $ 746,800,000
Principal outstanding 510,000,000    
Secured debt | 2024-1 CLO, Class A Notes, Senior Secured Floating Rate      
Debt Instrument [Line Items]      
Principal outstanding $ 0    
Basis spread on variable rate 151.00%    
Secured debt | 2024-1 CLO, Class A-L Loans, Senior Secured Floating Rate      
Debt Instrument [Line Items]      
Principal outstanding $ 412,500,000    
Basis spread on variable rate 151.00%    
Secured debt | 2024-1 CLO, Class B Notes, Senior Secured Floating Rate      
Debt Instrument [Line Items]      
Principal outstanding $ 45,000,000    
Basis spread on variable rate 178.00%    
Secured debt | 2024-1 CLO, Class C Notes, Mezzanine Secured Deferrable Floating Rate      
Debt Instrument [Line Items]      
Principal outstanding $ 52,500,000    
Basis spread on variable rate 200.00%    
Subordinated Debt | 2024-1 CLO Debt      
Debt Instrument [Line Items]      
Principal outstanding $ 236,770,000    
[1] All securities are exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”) and may be deemed to be “restricted securities.” As of June 30, 2026, the aggregate fair value of these securities is $13,364.3 million or 225.04% of the Company’s net assets. The initial acquisition dates have been included for such securities.
[2] Unless otherwise indicated, all debt and equity investments held by the Company (which such term “Company” shall include the Company’s consolidated subsidiaries for purposes of this Condensed Consolidated Schedule of Investments) are denominated in U.S. dollars. As of June 30, 2026, the Company had investments denominated in Canadian Dollars (CAD), Euros (EUR), British Pounds (GBP), Danish Krone (DKK), Swedish Krona (SEK), Norwegian Krone (NOK), and Australian Dollars (AUD). All debt investments are income producing unless otherwise indicated. All equity investments are non-income producing unless otherwise noted. Certain portfolio company investments are subject to contractual restrictions on sales. The total par amount (in thousands) is presented for debt investments, while the number of shares or units (in whole amounts) owned is presented for equity investments. Each of the Company’s investments is pledged as collateral, under one or more of its credit facilities unless otherwise indicated.
[3] All securities are exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), excluding Axsome Therapeutics, Inc. - Common Stock, and may be deemed to be “restricted securities.” As of December 31, 2025, the aggregate fair value of these securities is $14,206.9 million or 227.48% of the Company’s net assets. The initial acquisition dates have been included for such securities.
[4] Unless otherwise indicated, all debt and equity investments held by the Company (which such term “Company” shall include the Company’s consolidated subsidiaries for purposes of this Condensed Consolidated Schedule of Investments) are denominated in U.S. dollars. As of December 31, 2025, the Company had investments denominated in Canadian Dollars (CAD), Euros (EUR), British Pounds (GBP), Danish Krone (DKK), Swedish Krona (SEK), Norwegian Krone (NOK), and Australian Dollars (AUD). All debt investments are income producing unless otherwise indicated. All equity investments are non-income producing unless otherwise noted. Certain portfolio company investments are subject to contractual restrictions on sales. The total par amount (in thousands) is presented for debt investments, while the number of shares or units (in whole amounts) owned is presented for equity investments. Each of the Company’s investments is pledged as collateral, under one or more of its credit facilities unless otherwise indicated.